Cambridge, Massachusetts, USA, April 21, 2026

In a transformative step for AI-driven biotechnology and longevity science, Insilico Medicine has announced the formation of the industry’s first Longevity Board, a strategic initiative designed to accelerate aging research and next-generation drug discovery. This pioneering move aims to integrate generative artificial intelligence (AI) with cutting-edge biological research to develop therapies targeting the fundamental mechanisms of aging, shifting healthcare from a reactive disease model to a proactive approach focused on healthspan and peakspan extension. The Board will provide scientific oversight and strategic guidance across key areas, including biomarkers of aging, life modeling, dual-purpose therapeutic targets, and clinical validation, marking a major milestone in the evolution of precision medicine and longevity therapeutics.

Bridging AI Innovation with Big Pharma Expertise

The newly established Longevity Board brings together a distinguished group of leaders from both pharmaceutical research and longevity science, creating a powerful synergy between academic insight, biotech innovation, and large-scale drug development expertise. The Board is chaired by Dr. Andrew Adams, Group Vice President of Molecular Discovery at Eli Lilly and Company, whose leadership is expected to bridge the gap between experimental longevity science and commercial pharmaceutical development.

The inclusion of globally recognized experts such as Nobel Laureate Dr. Michael Levitt further strengthens the Board’s scientific foundation. By combining deep biological knowledge with AI-powered drug discovery platforms, Insilico aims to accelerate the transition of experimental compounds into clinically viable therapies, enhancing efficiency and success rates in drug development.

AI-Driven Approach to Aging and Disease

Advertisement

cGxPJobs Banner

Insilico Medicine is at the forefront of a new paradigm in longevity research, focusing on dual-purpose therapeutics that simultaneously target age-related diseases and the biological processes of aging. Rather than pursuing traditional “anti-aging” strategies, the company leverages its generative AI platform to identify molecular targets linked to both chronic diseases and aging pathways, enabling the development of therapies with broader clinical impact.

This approach is particularly relevant for conditions such as metabolic disorders, cancer, fibrosis, and muscle degeneration, which are closely associated with aging. By utilizing AI-driven modeling, biomarker analysis, and large-scale computational tools, Insilico is redefining how therapies are discovered, moving toward precision-targeted interventions that address root causes rather than symptoms.

Advancing the Future of Longevity Science

The creation of the Longevity Board reflects Insilico’s long-standing commitment to advancing longevity science, a field that has evolved significantly over the past decade. With more than 50 research publications in aging and drug discovery, the company has established itself as a leader in AI-enabled biomedical innovation. The Board’s work will focus on validating therapies that influence the hallmarks of aging, using advanced biomarkers and foundation AI models to measure clinical outcomes.

This initiative aligns with global trends toward preventive healthcare and personalized medicine, where extending healthy lifespan is becoming a key objective. By integrating computational power with biological complexity, Insilico aims to unlock new therapeutic possibilities that could fundamentally reshape the future of healthcare and aging research.

Overall, Insilico Medicine’s launch of the Longevity Board represents a groundbreaking advancement in the convergence of artificial intelligence, drug discovery, and aging science. By fostering collaboration between AI experts, clinicians, and pharmaceutical leaders, the company is paving the way for next-generation therapeutics that could significantly improve human healthspan and quality of life, marking a new era in precision longevity medicine.

Source: Insilico Medicine press release